Literature DB >> 15004556

ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance.

Elizabeth K Brint1, Damo Xu, Haiying Liu, Aisling Dunne, Andrew N J McKenzie, Luke A J O'Neill, Foo Y Liew.   

Abstract

The Toll-interleukin 1 receptor (TIR) superfamily, defined by the presence of an intracellular TIR domain, initiates innate immunity through activation of the transcription factor NF-kappa B, leading to the production of proinflammatory cytokines. ST2 is a member of the TIR family that does not activate NF-kappa B and has been suggested as an important effector molecule of T helper type 2 (T(H)2) responses. We show here that the membrane-bound form of ST2 negatively regulated type I interleukin 1 receptor (IL-1RI) and Toll-like receptor 4 (TLR4) but not TLR3 signaling by sequestrating the adaptors MyD88 and Mal. In contrast to wild-type mice, ST2-deficient mice failed to develop endotoxin tolerance. Thus, these results provide a molecular explanation for the function of ST2 in T(H)2 responses, as inhibition of TLRs promotes a T(H)2 response, and also identify ST2 as a key regulator of endotoxin tolerance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004556     DOI: 10.1038/ni1050

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  162 in total

1.  S-adenosylmethionine prevents the up regulation of Toll-like receptor (TLR) signaling caused by chronic ethanol feeding in rats.

Authors:  Joan Oliva; Fawzia Bardag-Gorce; Jun Li; Barbara A French; Samuel W French
Journal:  Exp Mol Pathol       Date:  2011-01-25       Impact factor: 3.362

Review 2.  Highlights of the advances in basic immunology in 2011.

Authors:  Juan Liu; Shuxun Liu; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2012-04-23       Impact factor: 11.530

3.  Differential regulation of Toll-like receptor signalling in spleen and Peyer's patch dendritic cells.

Authors:  Julie M Davies; John MacSharry; Fergus Shanahan
Journal:  Immunology       Date:  2010-11       Impact factor: 7.397

4.  Interleukin-33 safeguards neutrophils in sepsis.

Authors:  Thierry Roger; Thierry Calandra
Journal:  Nat Med       Date:  2010-06       Impact factor: 53.440

5.  Down-regulation of single immunoglobulin interleukin-1R-related molecule (SIGIRR)/TIR8 expression in intestinal epithelial cells during inflammation.

Authors:  C Kadota; S Ishihara; M M Aziz; M A Rumi; N Oshima; Y Mishima; I Moriyama; T Yuki; Y Amano; Y Kinoshita
Journal:  Clin Exp Immunol       Date:  2010-11       Impact factor: 4.330

6.  A Structural View of Negative Regulation of the Toll-like Receptor-Mediated Inflammatory Pathway.

Authors:  Emine Guven-Maiorov; Ozlem Keskin; Attila Gursoy; Ruth Nussinov
Journal:  Biophys J       Date:  2015-08-11       Impact factor: 4.033

7.  Contradictory functions (activation/termination) of neutrophil proteinase 3 enzyme (PR3) in interleukin-33 biological activity.

Authors:  Suyoung Bae; Taebong Kang; Jaewoo Hong; Siyoung Lee; Jida Choi; Hyunjhung Jhun; Areum Kwak; Kwangwon Hong; Eunsom Kim; Seunghyun Jo; Soohyun Kim
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

8.  Anti-inflammatory Effects of Oct4/Sox2-overexpressing Human Adipose Tissue-derived Mesenchymal Stem Cells.

Authors:  Qiang Li; Sei-Myoung Han; Woo-Jin Song; Sang-Chul Park; Min-Ok Ryu; Hwa-Young Youn
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

9.  Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33.

Authors:  Tatjana Pecaric-Petkovic; Svetlana A Didichenko; Sacha Kaempfer; Nicole Spiegl; Clemens A Dahinden
Journal:  Blood       Date:  2008-10-27       Impact factor: 22.113

10.  IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells.

Authors:  Heth R Turnquist; Tina L Sumpter; Allan Tsung; Alan F Zahorchak; Atsunori Nakao; Gerard J Nau; Foo Y Liew; David A Geller; Angus W Thomson
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.